Letairis is a medication formulated as an oral antihistamine used to treat allergic conditions. It is indicated for relief of symptoms such as sneezing, itching, rhinorrhea, and conjunctival irritation associated with allergic rhinitis. The drug functions by selectively blocking histamine h1 receptors on peripheral tissues. This blockade prevents histamine from binding to its receptors and thereby reduces vascular permeability and inflammatory signaling. Letairis is absorbed from the gastrointestinal tract and reaches peak plasma concentrations within a few hours. It undergoes hepatic metabolism primarily through cytochrome p450 enzymes and is eliminated mainly via renal excretion. The pharmacological effect contributes to the mitigation of inflammatory mediators released during the allergic response. Overall the medication provides symptomatic control without directly altering the underlying immune response.

Letairis is a medication classified as an endothelin receptor antagonist used primarily for the treatment of pulmonary arterial hypertension. Its pharmacological action involves selective binding to the endothelin type a and b receptors on vascular smooth muscle cells, preventing the vasoconstrictive effects of endothelin. By blocking these receptors, Letairis reduces vascular resistance and pulmonary artery pressure, which improves blood flow and reduces the workload on the right side of the heart. This mechanism also helps to attenuate vascular remodeling, slowing the progression of disease. The resulting vasodilation leads to measurable improvements in exercise capacity, as reflected by increased six-minute walk distance in clinical studies. Letairis is formulated as an oral tablet that is absorbed consistently across a wide range of body mass indices, providing predictable pharmacokinetic exposure. The drug is metabolized primarily by cytochrome p450 enzymes in the liver, producing inactive metabolites that are eliminated through the biliary system. Overall, the medication's ability to modulate endothelin signaling underlies its therapeutic role in managing symptoms and delaying disease advancement in patients with pulmonary arterial hypertension

Letairis may cause dizziness or lightheadedness in some patients. It can also lead to dry mouth or constipation as gastrointestinal side effects. Some individuals report mild headache or fatigue during treatment. Rarely users experience skin rash or itching that requires attention. The medication has been associated with occasional mild swelling of the hands or feet. Most reported effects are temporary and resolve with continued use.

Letairis may cause headache or dizziness in some patients. Nausea and vomiting are reported side effects of the medication. Fatigue and weakness can occur during treatment. Some users experience dry cough or throat irritation. Changes in blood pressure or heart rate have been observed rarely. Skin reactions such as rash or itching may develop. Elevated liver enzymes are occasionally detected in laboratory tests.